Why the study?
Managing advanced HF complicated by cardiorenal syndrome and diuretic resistance is challenging, often necessitating kidney replacement therapy for persistent congestion and worsening kidney function.
This review highlights the role of extracorporeal and peritoneal-based kidney replacement therapies as a solution for advanced heart failure patients with cardiorenal syndrome and diuretic resistance.
Answers are grounded in this paper and cite their sources.
May inform diuretic-resistant cardiorenal syndrome management; leaves open need for randomized trials before practice change.
Heart failure (HF) is a major health problem because of its high prevalence, morbidity, mortality, and cost of care. An important contributor to morbidity and mortality in patients with advanced HF is kidney dysfunction. Almost half of HF patients develop cardiorenal syndrome (CRS). The management of advanced HF complicated by CRS is challenging. Two main strategies have been widely accepted for the management of CRS, namely improving cardiac output and relieving congestion. Diuretics remain the cornerstone and first-line therapy for decongestion; however, a substantial number of CRS patients develop diuretic resistance. In the face of persistent congestion and the progressive deterioration of kidney function, the implementation of kidney replacement therapy may become the only solution. In the review the current evidence on extracorporeal and peritoneal-based kidney replacement techniques for the therapy of CRS patients are presented.
No takes yet. Share an insight, caveat, or question.
Wojtaszek et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: